Core Insights - Recursion has reached a pivotal moment, transitioning from demonstrating AI's role in drug discovery to showcasing an AI-native operating system that can generate clinical proof and sustainable value [3] - The company enters 2026 with five clinical programs advancing and over $500 million in milestone payments earned to date, reflecting a robust pipeline and disciplined execution strategy [3][6] Business Highlights - Recursion's pipeline is diversified, powered by its AI-native Recursion OS, with both wholly-owned and partnered programs [4] - The company achieved its first clinical validation of the Recursion OS in Familial Adenomatous Polyposis (FAP), with 75% of evaluable patients showing reductions in total polyp burden [6][9] - Recursion has received $134 million in milestone payments from its collaboration with Sanofi, with five discovery program packages accepted to date [6][14] Financial Performance - Total revenue for Q4 2025 was $35.5 million, a significant increase from $4.5 million in Q4 2024, driven by milestone payments and collaboration agreements [15] - Research and development expenses for Q4 2025 were $95.9 million, slightly lower than $98.3 million in Q4 2024, while total R&D expenses for the year were $475.3 million compared to $314.4 million in 2024 [15][22] - The net loss for Q4 2025 was $108.1 million, an improvement from a net loss of $178.9 million in Q4 2024, with a total net loss of $644.8 million for the year [15][22] Pipeline and Milestones - Recursion's pipeline includes several promising candidates, such as REC-4881 for FAP, REC-617 for advanced solid tumors, and REC-7735 for PI3Kα H1047R mutation [7][9] - Upcoming milestones include FDA engagement for REC-4881 and additional Phase 1/2 clinical data expected in 2026 [9][12] - The company anticipates further advancements in its partnered discovery programs, with potential for additional near-term milestones as programs progress [8][14] Cash Position - As of December 31, 2025, Recursion had cash and cash equivalents of $754 million, providing a runway into early 2028 without additional financing [6][15] - The company achieved a cash operating expense of approximately $399.2 million for 2025, reflecting improved operational efficiency [12][22]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had divested all its stake in the company. Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts The giant semiconductor company exited its previous holding of 7.71 million shares in Recursion Pharmaceuticals, which is making a name for itself by levera ...

Core Insights - Recursion, a clinical stage TechBio company, will be featured in a Lightning Talk at the NVIDIA GTC AI Conference, focusing on the integration of AI, automation, and robotics in drug discovery and development [1][4] Company Overview - Recursion is a leading TechBio company that decodes biology to improve lives, utilizing a platform called Recursion OS to generate one of the largest proprietary biological and chemical datasets [5] - The company operates sophisticated integrated wet and dry labs for AI drug discovery, generating millions of multi-omic data points weekly to enhance the drug discovery process [3][5] - Recursion's operations are supported by its powerful supercomputer, BioHive-2, which facilitates end-to-end improvements in drug discovery, including biological discoveries, precision drug design, and optimized clinical trials [3][5] Collaboration and Technology - Recursion is collaborating with HighRes Biosolutions to develop self-driving, high-throughput labs using advanced automation and orchestration technologies [2] - The collaboration leverages HighRes technologies such as robotic perception and digital twins of laboratory environments, which are essential for creating self-driving laboratories [2] Industry Impact - The advancements in AI and accelerated computing are pushing the boundaries of drug discovery, with NVIDIA's involvement highlighting the transition from concept to reality in Physical AI [4]

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $3.42, reflecting an -8.06% change from the previous day, underperforming the S&P 500 which gained 0.69% [1] - Prior to the latest trading session, RXRX shares had decreased by 25%, lagging behind the Medical sector's gain of 0.77% and the S&P 500's loss of 1% [1] Upcoming Financial Results - Recursion Pharmaceuticals is set to announce its earnings on February 25, 2026, with an expected EPS of -$0.28, indicating a 47.17% growth compared to the same quarter last year [2] - Revenue is projected to be $25.5 million, representing a significant 460.44% increase compared to the year-ago quarter [2] Full-Year Estimates - The Zacks Consensus Estimates for RXRX indicate expected earnings of -$1.59 per share and revenue of $64.62 million, reflecting year-over-year changes of +5.92% and +9.83%, respectively [3] - Recent modifications to analyst estimates for Recursion Pharmaceuticals suggest positive near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate remaining unchanged over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries, indicating strong performance potential [6]

When artificial intelligence (AI) chip maker NVIDIA Corporation (NVDA) heads for the exit, investors instinctively glance at the door. In its latest 13F filing, the chip giant disclosed that it had completely exited its position in the AI-driven drug developer Recursion Pharmaceuticals (RXRX). At the end of Q3 2025, Nvidia held 7.71 million shares. The stake represented a modest slice of its expansive, meticulously managed AI portfolio. Still, the headline carried weight. Traders pushed the stock down as ...

周三，Recursion Pharmaceuticals(RXRX.US)盘前股价暴跌，截至发稿，该股跌超13%，报3.46美元。消 息面上，英伟达(NVDA.US)向美国SEC递交的13F文件显示，其在2025年四季度清仓了Recursion Pharmaceuticals。 来源：智通财经网 ...

智通财经APP获悉，周三，Recursion Pharmaceuticals(RXRX.US)盘前股价暴跌，截至发稿，该股跌超 13%，报3.46美元。消息面上，英伟达(NVDA.US)向美国SEC递交的13F文件显示，其在2025年四季度 清仓了Recursion Pharmaceuticals。 ...

Core Insights - Recursion, a clinical stage TechBio company, will provide business updates and report its fourth quarter and full year 2025 financial results on February 25, 2026, before the market opens [1] - The company will host a live earnings call on the same day at 8:00 am ET, allowing investors and the public to submit questions [2] Company Overview - Recursion is focused on decoding biology to improve lives, utilizing its Recursion OS platform to generate one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, operating at a scale of millions of wet lab experiments weekly [3] - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, with additional offices in Montréal, New York, London, and the Oxford area [4]

Core Insights - Recursion, a clinical stage TechBio company, has granted inducement restricted stock unit (RSU) awards covering 820,431 shares to 17 new employees as part of its 2024 Inducement Equity Incentive Plan [1][2] Group 1: Inducement RSU Awards - The RSU awards will vest 25% on the first quarterly vesting date after one year from the vesting commencement date, followed by 1/16th of the shares on each subsequent quarterly vesting date [2] - The awards are contingent upon the continued employment of the recipients through the vesting dates and are governed by the terms of the 2024 Plan and grant agreements [2] Group 2: Company Overview - Recursion is focused on decoding biology to improve lives, utilizing a platform known as Recursion OS, which generates one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [3] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers globally, integrating technology, biology, and chemistry to advance medicine [3] Group 3: Company Location and Presence - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [4] - The company has additional offices in Montréal, New York, London, and the Oxford area [4]

Core Viewpoint - Recursion Pharmaceuticals is experiencing a decline in stock performance, with a notable drop of 17.26% over the past month, which is significantly worse than the broader market indices [1] Financial Performance - The upcoming financial results for Recursion Pharmaceuticals are expected to show an EPS of -$0.28, representing a 47.17% increase compared to the same quarter last year [2] - Revenue is anticipated to reach $25.5 million, reflecting a substantial increase of 460.44% from the prior-year quarter [2] - For the full year, earnings are projected at -$1.59 per share and revenue at $64.62 million, indicating increases of 5.92% and 9.83% respectively from the previous year [3] Analyst Estimates - Recent changes in analyst estimates for Recursion Pharmaceuticals suggest a positive outlook for the business, as positive revisions are often indicative of favorable near-term trends [3][4] - The Zacks Rank system currently rates Recursion Pharmaceuticals as 2 (Buy), indicating a favorable investment outlook [5] Industry Context - Recursion Pharmaceuticals operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 86, placing it in the top 36% of over 250 industries [6] - The Zacks Industry Rank is based on the average Zacks Rank of individual stocks, with top-rated industries historically outperforming lower-rated ones by a factor of 2 to 1 [6]